HR 5958 · 118th Congress 2023โ€“2025, ended

Drug-price Transparency for Consumers Act of 2023

Latest action · Dec 17, 2024 Referred to the Subcommittee on Health.

Progress

Where this bill reached, and when. A stage with no date was not reached; one that failed a vote and later carried shows the date it carried.

  1. IntroducedOct 13, 2023
  2. Passed HouseNot reached
  3. Passed SenateNot reached
  4. To the PresidentNot reached
  5. Became lawNot reached

Cosponsors 1

Members who signed on, in the order they did. All signed on Oct 13, 2023.

SeatCosponsorSigned on
R-IAZachary NunnOriginalOct 13, 2023

Committees 2

Where it was sent and what each committee and subcommittee did with it, in order.

ChamberCommitteeWhat it did
HouseEnergy and Commerce Committee
Referred Oct 25, 2023
HouseWays and Means Committee
Referred Oct 25, 2023
Health Subcommittee
Referred Dec 17, 2024

Actions 3

Everything that happened, newest first.

  1. Dec 17, 2024Referred to the Subcommittee on Health.
  2. Oct 25, 2023Referred to the Committee on Energy and Commerce, and in addition to the Committee on Ways and Means, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.
  3. Oct 13, 2023Introduced in House

Research

What has been written about this bill: committee reports, cost estimates, the sponsor’s authority statement, printed hearings and the Congressional Research Service’s work.

Constitutional authority

[Pages H5013-H5014] From the Congressional Record Online through the Government Publishing Office [ www.gpo.gov ] By Ms. SPANBERGER: H.R. 5958. Congress has the power to enact this legislation pursuant to the following: Article I, Section 8, Clause 3 The Congress shall have Power . . . To regulate Commerce with foreign Nations, and among the several States, and with the Indian Tribes. The single subject of this legislation is: To require pharmaceutical companies to disclose the list price of their drug in direct-to-consumer advertising.

The sponsor’s statement, as printed in the Congressional Record, vol. 169, no. 168, October 13, 2023, page H5014.

Related bills 1

Companion bills and other measures the record links to this one.

BillTitleRelationshipLatest action
S 1250Drug-price Transparency for Consumers Act of 2023Identical billApr 20, 2023

Titles 2

Every title it has carried, official and short, at each stage.

Official Title as Introduced
To amend title XI of the Social Security Act to require that direct-to-consumer advertisements for drugs and biologicals include an appropriate disclosure of pricing information.
Short Title(s) as Introduced
Drug-price Transparency for Consumers Act of 2023

Subjects

Assigned by the Library of Congress. Policy area: Health.

Text 1

Each version as it was printed, newest first.

  1. Oct 25, 2023Introduced in House

Support LegiList

This page is free, carries no paywall, and is built and maintained by one person. If the record here is useful to you, a few dollars keeps it going.

Processed by Stripe in a separate window. LegiList never sees card details.

Everything here is as published by Congress: the summary is the Congressional Research Service's, the action wording is the clerks', and the subjects are the Library of Congress's. How far it got is read from the actions themselves, taking the most recent one of each kind, so a bill that failed a vote and later passed is shown as having passed. Records come from this bill on Congress.gov and govinfo.gov; cost estimates are the Congressional Budget Office's, and the hearings are the printed hearings GovInfo publishes, which can appear months after the hearing.